Clinical Trial Update: A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of Iressa (gefitinib) and Faslodex (fulvestrant) in patients with advanced or metastatic breast cancer has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED